These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 8757193)
1. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. Roy DC; Ouellet S; Le Houillier C; Ariniello PD; Perreault C; Lambert JM J Natl Cancer Inst; 1996 Aug; 88(16):1136-45. PubMed ID: 8757193 [TBL] [Abstract][Full Text] [Related]
2. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. Lynch TJ; Lambert JM; Coral F; Shefner J; Wen P; Blattler WA; Collinson AR; Ariniello PD; Braman G; Cook S; Esseltine D; Elias A; Skarin A; Ritz J J Clin Oncol; 1997 Feb; 15(2):723-34. PubMed ID: 9053498 [TBL] [Abstract][Full Text] [Related]
4. Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer. Epstein C; Lynch T; Shefner J; Wen P; Maxted D; Braman V; Ariniello P; Coral F; Ritz J Int J Cancer Suppl; 1994; 8():57-9. PubMed ID: 7515030 [TBL] [Abstract][Full Text] [Related]
5. Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. Johnson BE; Kelley MJ Oncology (Williston Park); 1998 Jan; 12(1 Suppl 2):11-4. PubMed ID: 9516605 [TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of a blocked ricin immunotoxin with specificity against the cluster-5A antigen associated with human small-cell lung cancer. Zangemeister-Wittke U; Collinson AR; Fisch I; Jones RM; Waibel R; Lehman HP; Stahel RA Int J Cancer; 1993 Jul; 54(6):1028-35. PubMed ID: 8392978 [TBL] [Abstract][Full Text] [Related]
7. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Roy DC; Griffin JD; Belvin M; Blättler WA; Lambert JM; Ritz J Blood; 1991 Jun; 77(11):2404-12. PubMed ID: 2039821 [TBL] [Abstract][Full Text] [Related]
8. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies. Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879 [TBL] [Abstract][Full Text] [Related]
9. Immunotoxins recognising a new epitope on the neural cell adhesion molecule have potent cytotoxic effects against small cell lung cancer. Zangemeister-Wittke U; Collinson AR; Frösch B; Waibel R; Schenker T; Stahel RA Br J Cancer; 1994 Jan; 69(1):32-9. PubMed ID: 7506925 [TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of L6-ricin immunotoxin against the H2981-T3 lung adenocarcinoma cell line in vitro and in vivo. Schmidberger H; King L; Lasky LC; Vallera DA Cancer Res; 1990 Jun; 50(11):3249-56. PubMed ID: 1692258 [TBL] [Abstract][Full Text] [Related]
11. Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Shah SA; Halloran PM; Ferris CA; Levine BA; Bourret LA; Goldmacher VS; Blättler WA Cancer Res; 1993 Mar; 53(6):1360-7. PubMed ID: 7680284 [TBL] [Abstract][Full Text] [Related]
12. Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. La Russa VF; Griffin JD; Kessler SW; Cutting MA; Knight RD; Blattler WA; Lambert JM; Wright DG Exp Hematol; 1992 May; 20(4):442-8. PubMed ID: 1373688 [TBL] [Abstract][Full Text] [Related]
13. Elimination of B-lineage leukemia and lymphoma cells from bone marrow grafts using anti-B4-blocked-ricin immunotoxin. Roy DC; Perreault C; Bélanger R; Gyger M; Le Houillier C; Blättler WA; Lambert JM; Ritz J J Clin Immunol; 1995 Jan; 15(1):51-7. PubMed ID: 7539011 [TBL] [Abstract][Full Text] [Related]
14. Phase II clinical trial of bolus infusion anti-B4 blocked ricin immunoconjugate in patients with relapsed B-cell non-Hodgkin's lymphoma. Multani PS; O'Day S; Nadler LM; Grossbard ML Clin Cancer Res; 1998 Nov; 4(11):2599-604. PubMed ID: 9829722 [TBL] [Abstract][Full Text] [Related]
15. Potent and specific killing of human malignant brain tumor cells by an anti-transferrin receptor antibody-ricin immunotoxin. Zovickian J; Johnson VG; Youle RJ J Neurosurg; 1987 Jun; 66(6):850-61. PubMed ID: 3033171 [TBL] [Abstract][Full Text] [Related]
16. Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer. Derbyshire EJ; Stahel RA; Wawrzynczak EJ Cancer Immunol Immunother; 1992; 35(6):417-20. PubMed ID: 1327529 [TBL] [Abstract][Full Text] [Related]
17. Refinement of an indirect immunotoxin assay of monoclonal antibodies recognising the human small cell lung cancer cluster 2 antigen. Derbyshire EJ; de Leij L; Wawrzynczak EJ Br J Cancer; 1993 Jun; 67(6):1242-7. PubMed ID: 8390281 [TBL] [Abstract][Full Text] [Related]
18. Anti-CD38-blocked ricin: an immunotoxin for the treatment of multiple myeloma. Goldmacher VS; Bourret LA; Levine BA; Rasmussen RA; Pourshadi M; Lambert JM; Anderson KC Blood; 1994 Nov; 84(9):3017-25. PubMed ID: 7524764 [TBL] [Abstract][Full Text] [Related]
19. A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells. Krueger P; Nitz C; Foster R; MacDonald C; Gelber O; Lalehzadeh G; Goodson R; Winter J; Gelber C Cancer Immunol Immunother; 2003 Jun; 52(6):367-77. PubMed ID: 12669243 [TBL] [Abstract][Full Text] [Related]
20. Restoration of interferon alpha potentiation of a recombinant ricin A chain immunotoxin following cytoreduction of xenografts of advanced ovarian tumors. Pearson JW; Fogler WE; Volker K; Riggs CW; Gruys E; Groves ES; Wiltrout RH; Longo DL J Natl Cancer Inst; 1993 Jun; 85(11):907-12. PubMed ID: 8492319 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]